Table 3.

Effects of PI-083 and Bortezomib on primary multiple myeloma cells isolated from patients’ bone marrow (IC₅₀ values, μM)

Patient No.	CT-L Activity		Proliferation		Cell Death		Viability
	24 h		24 h		24 h		24 h		48 h		72 h
	PI-083	Bortezomib	PI-083	Bortezomib	PI-083	Bortezomib	PI-083	Bortezomib	PI-083	Bortezomib	PI-083	Bortezomib
1	2.1	0.0054	5	> 10	7.3	> 10	ND	ND	ND	ND	ND	ND
2	1.5	0.062	2.9	> 10	3.2	> 10	> 10	> 10	ND	ND	ND	ND
3	1.4	0.0015	6.6	> 10	6.2	> 10	> 10	> 10	ND	ND	ND	ND
4	0.68	0.0031	1.3	> 10	2. 7	> 10	2.2	> 10	2.6	0.45	2.2	0.052
5	0.57	0.0046	2.2	> 10	1.1	> 10	3.4	> 10	3.6	0.079	2.6	0.074
6	1.2	0.015	2.2	> 10	2.7	> 10	2.1	> 10	0.9	0.055	1.4	0.054
7	0.57	0.0034	2.6	> 10	2.4	> 10	1.8	> 10	1.4	> 10	1.3	0.023
8	2.1	0.004	1.7	> 10	1.7	> 10	2.0	0.19	1.5	0.064	1.8	0.052
9	1.8	0.0028	2.8	> 10	4.1	> 10	1.4	0.28	0.89	0.032	0.35	0.02
10	0.78	0.017	10	> 10	9.0	> 10	> 10	> 10	ND	ND	ND	ND